A5056454945- Pharmacogenetics and Drug Metabolism
- Drug Transport and Resistance Mechanisms
- Pharmaceutical studies and practices
- Schizophrenia research and treatment
- Pharmacological Effects and Toxicity Studies
- Computational Drug Discovery Methods
- Cardiac electrophysiology and arrhythmias
- Drug-Induced Hepatotoxicity and Protection
- Neonatal Health and Biochemistry
- Diet and metabolism studies
- Epilepsy research and treatment
- COVID-19 Clinical Research Studies
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Diabetes Treatment and Management
- Gastroesophageal reflux and treatments
- Bipolar Disorder and Treatment
- Pharmacology and Obesity Treatment
- COVID-19 Impact on Reproduction
- Ethics in Clinical Research
- Nausea and vomiting management
- Metabolism, Diabetes, and Cancer
- Asthma and respiratory diseases
- Nicotinic Acetylcholine Receptors Study
- Opioid Use Disorder Treatment
Hospital Universitario de La Princesa
2020-2025
Universidad Autónoma de Madrid
2020-2025
Hospital Universitario Príncipe de Asturias
2021
Universidad de Alcalá
2020
Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable
2020
Instituto de Salud Carlos III
2020
Consejo Superior de Investigaciones Científicas
2020
Hospital Universitario Puerta de Hierro Majadahonda
2020
Institute of Environmental Assessment and Water Research
2020
Several cytochrome P450 (CYP) CYP3A polymorphisms were associated with reduced enzyme function. We aimed to evaluate the influence of these alleles on pharmacokinetic parameters (PK) several substrates. included 251 healthy volunteers who received a single dose ambrisentan, atorvastatin, imatinib, aripiprazole, fentanyl, amlodipine, donepezil, olanzapine, fesoterodine, or quetiapine. The genotyped for CYP3A4 and CYP3A5 by qPCR. To compare PK across studies, measurements corrected mean each...
Background/Objectives: Pregabalin is a useful therapeutic option for patients with anxiety or neuropathic pain. Genetic variants in certain genes encoding transporters related to absorption and distribution could have an impact on the efficacy safety of drug. Furthermore, extreme phenotypes metabolic enzymes alter pregabalin-limited metabolism. Methods: In this study, we included 24 healthy volunteers participating bioequivalence clinical trial administered pregabalin 300 mg orally; 23...
Atorvastatin, prescribed for the treatment of hypercholesterolemia, demonstrated overwhelming benefits in reducing cardiovascular morbidity and mortality. However, many patients discontinue therapy due to adverse reactions, especially myopathy. The Dutch Pharmacogenetics Working Group (DPWG) recommends an alternative agent atorvastatin simvastatin or a dose adjustment depending on other risk factors statin-induced myopathy SLCO1B1 rs4149056 CC TC carriers. In contrast, Clinical...
Thiopurine drugs are purine nucleoside analogues used for treatment of different immune-related conditions. To date, studies highlighted the importance thiopurine methyltransferase (TPMT) genotyping in patients who initiate with thiopurines to make an adequate dose adjustment. We aimed investigate influence TPMT phenotype, concomitant treatments, and demographic characteristics on incidence adverse reactions (ADRs) start azathioprine (AZA). This was observational retrospective study. The...
Diazepam is a benzodiazepine (BZD) used worldwide for variety of conditions. Long-term use diazepam increases the risk developing tolerance and dependence occurrence adverse drug reactions (ADRs). CYP3A4 CYP2C19 mainly metabolize are therefore primary pharmacogenetic candidate biomarkers. In this work, we aimed to explore impact phenotypes 99 additional variants in other 31 pharmacogenes (including CYP, UGT, NAT2 CES enzymes, ABC SLC transporters) on pharmacokinetic variability safety. 30...
Amlodipine is an antihypertensive drug with unknown pharmacogenetic biomarkers. This research a candidate gene study that looked for associations between amlodipine pharmacokinetics and safety pharmacogenes. Pharmacokinetic data were taken from 160 volunteers eight bioequivalence trials. In the exploratory step, 70 genotyped 44 polymorphisms in different CYP2D6 poor metabolizers (PMs) showed higher half-life (t1/2) (univariate p-value (puv) = 0.039, multivariate (pmv) 0.013, β -5.31, R2...
For patients with type 2 diabetes, metformin is the most often recommended drug. However, there are substantial individual differences in pharmacological response to metformin. To investigate effect of transporter polymorphisms on pharmacokinetics an environment free confounding variables, we conducted our study healthy participants. This first investigation consider demographic characteristics alongside all transporters involved distribution. Pharmacokinetic parameters were found be...
Aims Pupillography is a noninvasive and cost‐effective method to determine autonomic nerve activity. Genetic variants in cytochrome P450 ( CYP ), dopamine receptor DRD2 , DRD3 serotonin HTR2A HTR2C ) ATP‐binding cassette subfamily B ABCB1 genes, among others, were previously associated with the pharmacokinetics pharmacodynamics of antipsychotic drugs. Our aim was evaluate effects aripiprazole olanzapine on pupillary light reflex related pharmacogenetics. Methods Twenty‐four healthy...
Aripiprazole and olanzapine are atypical antipsychotics. Both drugs can induce metabolic changes; however, the side effects produced by aripiprazole more benign. The aim of study was to evaluate if alter prolactin levels, lipid glucose metabolism hepatic, haematological, thyroid renal function. Twenty-four healthy volunteers received a daily oral dose 10 mg 5 tablets for days in crossover randomised clinical trial were genotyped 51 polymorphisms 18 genes qPCR. Drug plasma concentrations...
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to be related CYP2D6 pharmacogenetic phenotype. In contrast, scarce information is available nowadays concerning desvenlafaxine, its active metabolite first marketed in 2012. The aim of this study was evaluate the impact 29 alleles 12 candidate genes (e.g., CYP enzymes like CYP2D6, CYP3A4, or CYP2C19; ABC transporters ABCB1; SLCO1B1; UGT UGT1A1) on desvenlafaxine tolerability. Pharmacokinetic parameters...
Rivaroxaban is a direct inhibitor of factor Xa, member oral anticoagulant group drugs (DOACs). Despite being widely extended alternative to vitamin K antagonists (i.e., acenocoumarol, warfarin) the interindividual variability DOACs significant, and may be related adverse drug reaction occurrence or inefficacy, namely hemorrhagic thromboembolic events. Since there not consistent analytic practice monitor activity DOACs, previously reported polymorphisms in genes coding for proteins...
Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there a lack of histological remission in 50% patients. This research aimed to identify pharmacogenetic biomarkers predictive PPI effectiveness and study their association with disease features. Peak eosinophil count (PEC) endoscopic reference score (EREFS) were determined before after an eight-week course 28 EoE The impact signal transducer activator transcription 6...
Abstract Background In the first wave of COVID-19 pandemic, hypothesis that angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) increased risk and/or severity disease was widely spread. Consequently, in many hospitals, these drugs were discontinued as a “precautionary measure”. We aimed to assess whether in-hospital discontinuation ARBs or ACEIs, real-life conditions, associated with reduced death compared their continuation also compare head-to-head...
Abstract Cinitapride is a gastrointestinal prokinetic drug, prescribed for the treatment of functional dyspepsia, and as an adjuvant therapy gastroesophageal reflux disease. In this study, we aimed to explore impact relevant variants in CYP3A4 CYP2C8 other pharmacogenes, along with demographic characteristics, on cinitapride pharmacokinetics safety; evaluate alleles enzyme's function. Twenty‐five healthy volunteers participating bioequivalence clinical trial consented participate study....
Olanzapine is an atypical antipsychotic widely used for the treatment of schizophrenia, which often causes serious adverse drug reactions. Currently, there are no clinical guidelines implementing pharmacogenetic information on olanzapine. Moreover, Dutch Pharmacogenomics Working Group (DPWG) states that CYP2D6 phenotype not related to olanzapine response or side effects. Thus, objective this candidate-gene study was investigate effect 72 polymorphisms in 21 genes pharmacokinetics and safety,...
Abstract Objective To assess adverse events (AEs) and safety of aripiprazole (ARI) olanzapine (OLA) treatment. Methods Twenty‐four healthy volunteers receiving five daily oral doses 10 mg ARI 5 OLA in a crossover clinical trial were genotyped for 46 polymorphisms 14 genes by qPCR. Drug plasma concentrations measured high‐performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) 12‐lead electrocardiogram supine position. AEs also recorded. Results decreased diastolic BP...
Ramipril is an angiotensin-converting enzyme inhibitor used for hypertension and heart failure management. To date, scarce literature available on pharmacogenetic associations affecting ramipril. The goal of this study was to investigate the effect 120 genetic variants in 34 pharmacogenes (i.e., genes encoding enzymes like CYPs or UGTs transporters ABC SLC) ramipril pharmacokinetic variability adverse drug reaction (ADR) incidence. Twenty-nine healthy volunteers who had participated a...
Among cancer patients treated with fluoropyrimidines, 10-40% develop severe toxicity. Polymorphism of the dihydropyrimidine dehydrogenase (DPYD) gene may reduce DPD function, main enzyme responsible for metabolism fluoropyrimidines. This leads to drug accumulation and an increased risk Routine genotyping this gene, which usually includes DPYD *HapB3, *2A, *13 c.2846A > T (D949V) variants, helps predict approximately 20-30% toxicity cases. For intermediate (IM) or poor (PM) metabolizers, a...
Introduction Ezetimibe inhibits cholesterol uptake by modulation of intestinal sterol absorption. Currently, although some studies have shown alterations in ezetimibe levels caused the ABCG5 , ABCG8 NPC1L1 or UGT1A1 genes, there are no pharmacogenetic guidelines to confirm these biomarkers. The aim this work was evaluate effect 49 variants 22 pharmacogenes related metabolism and transport. Methods A total 96 healthy volunteers from four bioequivalence clinical trials as monotherapy...
Rasagiline is a selective and irreversible inhibitor of monoamine oxidase type B with neuroprotective effect, indicated for the management Parkinson's disease. The aim this work was to evaluate impact seven CYP1A2 alleles 120 additional variants located in other CYP enzymes (e.g., CYP2C19), UGT UGT1A1) or NAT2), transporters SLCO1B1) on pharmacokinetic variability safety rasagiline. A total 118 healthy volunteers enrolled four bioequivalence clinical trials consented participate...